TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05035862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-primed mesenchymal stromal cells (MSCs)
Description: IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
Study: NCT04951921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Pyruvate
Description: Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
Study: NCT04880278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
Study: NCT05319301

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: A single dose of melatonin (1.9 mg)
Study: NCT06079814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality intervention
Description: Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
Study: NCT06228170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT06262815

Intervention type: PROCEDURE
Intervention: Nasogastric tube placement
Description: Conventional nasogastric tube placement done for decompression of small bowel obstruction

Intervention type: PROCEDURE
Intervention: Nasogastric tube placement
Description: Conventional nasogastric tube placement done for decompression of small bowel obstruction

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: The scale described by Rockwood et al. categorizing patients \&gt;65 years of age on a 9 item scale depending on the frailty.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: The scale described by Rockwood et al. categorizing patients \&gt;65 years of age on a 9 item scale depending on the frailty.
Study: NCT05319301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: A single dose of melatonin (1.9 mg)
Study: NCT04790617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
Study: NCT06397079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Description: Teach Bass brushing technique and bursh teeth using electric toothbrush dental hygiene three times a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soft bristle toothbrush
Description: Teach Bass brushing technique and bursh teeth using soft bristle toothbrush dental hygiene three times a day.
Study: NCT05728437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: The program will consist of seven exercises: triceps press, biceps curl, lat pull down, calf raise, leg press, leg extension and sit-ups using dumbbells and sand bags. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance exercise that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last two weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. A 90-second rest will be allowed between sets of exercises.
Study: NCT06450899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine Maleate
Description: Currently, prochlorperazine maleate is approved by the FDA for the treatment of nausea and vomiting, and additionally used off-label as an acute migraine treatment. The FDA has approved the dose of 5-10 mg to be taken orally 3-4 times a day. The study intervention will be obtained from Belmar Pharma solutions. Individuals randomized into the study arm will receive generic prochlorperazine maleate 10 mg orally taken three times daily for one day. Participants will convene in the morning of the trial date at low altitude, where they will receive their first dose. They will then be driven to Summit Lake and break for lunch, where they will receive their second dose approximately 6 hours later. They will then hike to the summit and receive their final dose in the evening, approximately another 6 hours later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
Study: NCT05003505

Intervention type: OTHER
Intervention: Follow up
Description: Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
Study: NCT06394050

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: there is no intervention
Study: NCT05204719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Delivery Room Continuous Positive Airway Pressure
Description: Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
Study: NCT05659953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMT503
Description: Subjects will receive one of several different oral doses of LMT503 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one of several different oral doses of Placebo once daily
Study: NCT05839964

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format
Study: NCT05387200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masibone S
Description: The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax
Description: The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
Study: NCT06036225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Remote prehabilitation multi-component.
Study: NCT05944302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR group
Description: Eye Movement Desensitization and Reprocessing
Study: NCT05311709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: single group, all patients receive sotorasib
Study: NCT05122338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound lidocaine
Description: Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound lidocaine
Description: Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
Study: NCT05074992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Study: NCT05778604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physio-feedback
Description: The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational \| incongruent \| congruent \| rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reframing
Description: Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led exercises
Description: The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC older adults fall prevention
Description: Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
Study: NCT06322186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready-Heat Chemical Heating Blankets
Description: Ready-Heat blankets are 4-panel half blankets that generate an oxygen-activated exothermic effect in 8-15 minutes (i.e., no electricity required), providing warmth over 8 hours at up to 40 degrees Celsius.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warmed blankets or FAWB
Description: The current standard of care for hypothermic patients is applying two warmed blankets or forced air warming blankets (FAWB).
Study: NCT05266989

Intervention type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current

Intervention type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
Study: NCT06430970

Intervention type: DEVICE
Group type: OTHER
Intervention: endoscopy
Description: upper and lower endoscopy
Study: NCT06279234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: Oral tablet
Study: NCT05826743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLO BT™
Description: A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stoma Creation
Description: Protective ileostomy
Study: NCT06242132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT06169839

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.
Description: the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation
Description: the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality
Description: the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
Study: NCT06413992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel (albumin bound)
Description: Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel (albumin bound)
Description: Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin injection
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin injection
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External irradiation
Description: Non-essential, decision to combine is made by the principal investigator based on the patient's condition.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External irradiation
Description: Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
Study: NCT06262321

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Palliative Radiotherapy
Description: Prophylactic Palliative Radiotherapy